Mikhail Blagosklonny is an oncology professor that works at the Roswell Cancer Institute. He is a scientist that studies Cancer and Aging. He has had a massive education in the field of medicine. He attended the Pavlov State Medicine University in Petersburg. He was able to earn an MD in Internal Medicine at the University on LinkedIn. Mikhail furthered his studies to Ph.D. in the field of Cardiology and Experimental Medicine. He studied at the same school. Mikhail’s experience and research saw him become an associate professor of medicine at the Institute of New York Medical College in the year 2002. The college is located in Valhalla, New York.
Mikhail Blagosklonny joined Roswell Park as the Professor of Oncology in the year 2007. He has shown lots of experience and skills in his work. He has gained a massive experience in his work and has managed to become an excellent professor. He continues to research in other fields such as biology that deal with gaining. He has led several successful research work on tandfonline.com at the institute. He is known to have pioneered research in cancer, anti-aging drugs, and therapies that influence the presence of anti-aging drug cells.
Dr. Mikhail Blagosklonny has shown a tremendous interest in anti-aging. He has sought to create a possibility of using healthy cells from human beings and finding their causes of cancer. He has done deep research in cancer therapy. His research has seen him become famous for his work in TOR signaling and aging. He searches for the relationship between cancer drugs and extending the lifespan of individuals. Throughout his various activities, he has published several articles on Nature about his studies. He is known as the author of several academic journals today.
Oncotarget is an example of a Dr. Blagosklonny’s publication that was published in 2010. The journal was able to open a new access and new look in oncology and cancer research. It focused on new methods and techniques of innovative therapies on Google. Dr. Blagosklonny is also known as the chief editor of a popular journal called the Aging Cell. He discusses his findings in the field of oncology in the journal.